AI Summary & Key Takeaways
AI InsightThemedian overall survival and distant and regional recurrence-free and disease-specific survival was 96 months (range: 26–240), whiledisease-free and local recurrence-free survival was 96 months (range: 22–240).
📌 3 Key Takeaways
Abstract
Background/aim: The aim of this study was to evaluate the treatment results of patients undergoing adjuvant radiotherapy (ART) afterbreast surgery with the diagnosis of ductal carcinoma in situ (DCIS).Materials and methods: A total of 61 women who had undergone radiotherapy following extensive surgical excision were enrolled. Allpatients underwent 50 Gy ART. Survival analysis was performed using Kaplan–Meier analysis and SPSS 20.0.Results: The median age was 52 years (range: 28–86). The median follow-up period after RT was 92 months (range: 23–237). Themedian overall survival and distant and regional recurrence-free and disease-specific survival was 96 months (range: 26–240), whiledisease-free and local recurrence-free survival was 96 months (range: 22–240). While the 15-year and 20-year overall survival rates were87% and 87%, respectively, the recurrence-free survival rates were 98% and 98%, respectively; the rates of disease-specific survival were100% and 100%, respectively.Conclusion: The results of this study with a long follow-up period have shown that ART in DCIS is an effective treatment method toprovide local disease control. However, further large studies are needed to identify the prognostic factors.